Millennium Management’s Viking Therapeutics VKTX Stock Holding History

Millennium Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.63M	Buy	+50,000	New	+$1.61M	﹤0.01%	4049
2025 Q3	–	Sell	-20,000	Closed	-$530K	–	6501
2025 Q2	$530K	Buy	+20,000	New	+$526K	﹤0.01%	4868
2025 Q1	–	Sell	-9,500	Closed	-$382K	–	6438
2024 Q4	$382K	Buy	9,500 +1,200	+14%	+$68.4K	﹤0.01%	4928
2024 Q3	$525K	Sell	8,300 -3,300	-28%	-$194K	﹤0.01%	4793
2024 Q2	$615K	Buy	+11,600	New	+$760K	﹤0.01%	4458
2023 Q4	–	Sell	-44,800	Closed	-$496K	–	6587
2023 Q3	$496K	Buy	44,800 +1,800	+4%	+$25.7K	﹤0.01%	4670
2023 Q2	$697K	Sell	43,000 -188,000	-81%	-$3.94M	﹤0.01%	4311
2023 Q1	$3.85M	Buy	231,000 +191,000	+478%	+$1.97M	﹤0.01%	2843
2022 Q4	$376K	Buy	+40,000	New	+$179K	﹤0.01%	4943

Other funds holding VKTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Millennium Management's VKTX Position: Q1 2026 in Review

Millennium Management increased its Viking Therapeutics (VKTX) stake by 192% in Q1 2026, buying an estimated $5.29M and bringing the position to 250,525 shares worth $8.15M. The position accounts for ﹤0.01% of the portfolio, ranked #2378.

Millennium Management first reported a position in VKTX in Q4 2017 and has held it in 29 quarters since. The position peaked at $63.9M in Q1 2023. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

Millennium Management held 250,525 shares of Viking Therapeutics worth $8.15M as of Q1 2026.
Millennium Management bought 164,724 Viking Therapeutics shares in Q1 2026, an estimated $5.29M.
Viking Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2378 holding.
Millennium Management first reported a position in Viking Therapeutics in Q4 2017 and has held it in 29 quarters since.
Millennium Management's Viking Therapeutics position peaked at $63.9M in Q1 2023.
410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.